SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

PYXS

Pyxis Oncology
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming clinical updates in mid-2026 (monotherapy) and second half of 2026 (combination) for confirmation of clinical activity; positive data could drive significant upside in this low-market-cap biotech. Synergy with pembrolizumab may enhance partnership or licensing potential.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.70
T+0 close · Apr 17, 2026 · via day close
Latest settled
+42.94%
T+60 · $2.43
Vs SPY
+36.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $1.70entry
  2. T+1 · 7mo ago +0.59%α +1.24% · $1.71
  3. T+5 · 7mo ago +3.53%α +2.62% · $1.76
  4. T+20 · 6mo ago +18.82%α +14.62% · $2.02
  5. T+60 · 4mo ago +42.94%α +36.16% · $2.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-dependent tumor growth inhibition and synergistic anti-tumor activity when combined with anti-PD-1 therapy in an immunotherapy-refractory head and neck cancer model. These findings support ongoing clinical trials of MICVO as monotherapy and in combination with pembrolizumab for recurrent/metastatic HNSCC.

Key Facts

  • Preclinical data show maMICVO monotherapy inhibited tumor outgrowth in a syngeneic HNSCC model in a dose-dependent manner, with 6 mg/kg showing strongest effect
  • Combination of maMICVO and anti-mouse PD-1 showed synergistic anti-tumor activity in an immunotherapy-refractory model, with greater tumor control than either agent alone
  • maMICVO modulated the tumor immune environment by reducing regulatory T cells (Tregs), increasing CD8+ T cell-to-Treg ratio, and enhancing progenitor exhausted T cells responsive to anti-PD-1
  • Data to be presented at AACR 2026; supports ongoing Phase 1/2 trials of MICVO alone and with pembrolizumab in R/M HNSCC
  • MICVO has Fast Track Designation from FDA for R/M HNSCC previously treated with platinum and anti-PD-(L)1 therapy

Financial Impact

Non-material at this stage; preclinical data support clinical development but no revenue or earnings impact expected in near term

dilutioncash runway

Risk Factors

  • Preclinical results may not translate to clinical efficacy in humans
  • Clinical trial delays or safety issues could derail development
  • Low market cap ($107M) implies high risk; dependent on successful trial outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276488

Track record

25 reports on PYXS

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.03% at T+20 after the Sep 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026